Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Peritoneal Neoplasms × Letrozole × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 38 Endometrial Neoplasms 8 Polycystic Ovary Syndrome 3 Ovarian Neoplasms 3 Neoplasms 3 Fallopian Tube Neoplasms 3 Triple Negative Breast Neoplasms 2 Infertility, Female 2 Infertility 2 Carcinoma, Ovarian Epithelial 2 Carcinoma, Intraductal, Noninfiltrating 2 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Prostatic Neoplasms 1 Peritoneal Neoplasms 1 Pathologic Complete Response 1 Neoplasms by Site 1 Neoplasm Metastasis 1 Low-Grade Serous Ovarian Cancer 1 Low Grade Serous Ovarian Cancer 1 Locoregional Recurrence 1 Locally Advanced Breast Cancer 1 Leiomyoma 1 Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer 1 Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer 1 Hereditary Sensory and Autonomic Neuropathies 1 Hemangiosarcoma 1 Head and Neck Neoplasms 1

Interventions

Oxaliplatin 3 Mitomycin 3 Hyperthermic Intraperitoneal Chemotherapy 3 Cisplatin 3 sodium thiosulfate 2 Paclitaxel 2 Fluorouracil 2 Blood Specimen Collection 2 relacorilant 1 irinotecan sucrosofate 1 X-Rays 1 Pafolacianine 1 Observation 1 Neoadjuvant Therapy 1 Leucovorin 1 Letrozole 1 Doxorubicin 1 Docetaxel 1 Cytoreduction Surgical Procedures 1 Chemotherapy, Adjuvant 1 Bevacizumab 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04111978 2025-09-29

MATAO

Swiss GO Trial Group

Phase 3 Recruiting

Fallopian Tube Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡